Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05254327 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Trial of the Efficacy and Safety of Short and Long Course Radiation Therapy With/Without BMX-001

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 2 years 11 months later May 2027 → May 2030
See other at-risk trials from University of Nebraska

Record History

  1. Primary completion pushed from May 2027 to May 2030 Completion pushed from Jun 2029 to Jun 2034 · Eligibility criteria expanded, about 22 words · Site contacts updated at 1 of 3 sites · 1 more Show 4 more changesShow less
    • Completion pushed from Jun 2029 to Jun 2034
    • Eligibility criteria expanded, about 22 words
    • Site contacts updated at 1 of 3 sites
    • Publications: details revised at 1 of 1 entry
  2. Re-verified, no change to tracked fieldsv12
  3. Study sites: 1 to 3 Eligibility criteria shortened, about 45 wordsv11 Show 1 more changeShow less
    • Eligibility criteria shortened, about 45 words

    See this version in full on ClinicalTrials.gov ↗

  4. Re-verified, no change to tracked fieldsv10
  5. Primary completion date: Jan 2028 to May 2027 Completion date: Feb 2028 to Jun 2029v9 Show 1 more changeShow less
    • Completion date: Feb 2028 to Jun 2029
Show 7 earlier versionsHide 7 earlier versions
  1. Primary completion date: May 2028 to Jan 2028 Completion date: Dec 2033 to Feb 2028v8 Show 1 more changeShow less
    • Completion date: Dec 2033 to Feb 2028
  2. Primary completion date: May 2027 to May 2028 Completion date: Dec 2032 to Dec 2033v7 Show 1 more changeShow less
    • Completion date: Dec 2032 to Dec 2033
  3. Completion date: Jun 2029 to Dec 2032v6
  4. Site contact updatedv5
  5. Lead sponsor: Chi Lin, MD, PhD to University of Nebraska Trial status: Active, Not Recruiting to Recruiting · Site details revised · Collaborators: 2 to 1v4 Show 3 more changesShow less
    • Trial status: Active, Not Recruiting to Recruiting
    • Site details revised
    • Collaborators: 2 to 1

    See this version in full on ClinicalTrials.gov ↗

  6. Re-verified, no change to tracked fieldsv3
  7. Trial status: Not Yet Recruiting to Active, Not Recruiting Start date changed from estimate of Jun 2022 to Aug 15, 2022 · Site contact updatedv2 Show 2 more changesShow less
    • Start date changed from estimate of Jun 2022 to Aug 15, 2022
    • Site contact updated
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
In this Phase 2 study, we will conduct an efficacy and safety study of the combination of investigational drug BMX-001, with short-course radiotherapy (SCRT) or long-course chemoradiotherapy (LCCRT) as part of total neoadjuvant therapy in newly diagnosed rectal adenocarcinoma (RAC) patients.
Trial Details
NCT Number NCT05254327
Lead Sponsor University of Nebraska
Collaborators: BioMimetix JV, LLC
Conditions Rectal Cancer
Enrollment 118 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov